Stockscreener 앱 받기
9.12
0.33%
0.02
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 - MSN
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - MSN
Chart Watch: Can Seres Therapeutics Inc weather a recessionMarket Activity Report & Growth Focused Investment Plans - baoquankhu1.vn
Layoff Tracker: Gossamer, BiomX Reveal Hefty Staff Cuts - BioSpace
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date - The Globe and Mail
MCRB (NASDAQ: MCRB) files Form 144 to resell 8,553 restricted shares - Stock Titan
Kelly Brady Net Worth (2026) - GuruFocus
Seres Therapeutics schedules 2026 annual meeting for June 9 By Investing.com - Investing.com India
Seres Therapeutics schedules 2026 annual meeting for June 9 - Investing.com
Seres Therapeutics sets 2026 annual meeting for June 9; shareholder proposal deadline Mar 26 - TradingView
Seres Therapeutics (MCRB) schedules 2026 meeting, sets proposal deadline - Stock Titan
Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February - MarketBeat
MCRB: Canaccord Genuity Maintains Buy Rating with $22 Target | M - GuruFocus
Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
Exit Recap: Is Seres Therapeutics Inc impacted by rising rates2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Seres Therapeutics 2025 10-K: $0.8M Revenue, net income $5.70M - TradingView
Seres Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline - TipRanks
Seres (MCRB) Focuses on Advancing Biotherapeutics Portfolio - GuruFocus
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Seres Therapeutics: Fourth Quarter Earnings Overview - Bitget
Seres Therapeutics (NASDAQ: MCRB) details 2025 profit, cash runway and SER-155 progress - Stock Titan
Seres Therapeutics (MCRB) awards 56,250 stock options to officer - Stock Titan
Seres Therapeutics (MCRB) officer Brady Kelly reports stock holdings - Stock Titan
Seres Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Seres Therapeutics Inc expected to post a loss of $2.11 a shareEarnings Preview - TradingView
Is Seres Therapeutics Incs ROE strong enough2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Rally Mode: Should I invest in Seres Therapeutics Inc before earningsGold Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Activity Recap: Should I invest in Seres Therapeutics Inc before earningsWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Aug Action: Does Seres Therapeutics Inc have declining or rising EPSMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Seres Therapeutics (MCRB) director Richard Kender awarded 150,000 stock options - Stock Titan
Seres Therapeutics (MCRB) grants 75,000-share stock option to officer Henn - Stock Titan
Seres Therapeutics (MCRB) awards officer stock options for 22,500 shares - Stock Titan
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday - MarketBeat
Human Microbiome Therapeutics Market to Reach US$ 5.86 Billion - openPR.com
MCRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seres Therapeutics Announces Executive Leadership Changes and Promotions - The Globe and Mail
MCRB: Leadership transition and pipeline progress position the company for key clinical milestones in 2026 - TradingView
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates - The Manila Times
Seres Therapeutics appoints Kender as exec chair, interim CEO - National Today
[8-K] Seres Therapeutics, Inc. Reports Material Event | MCRB SEC FilingForm 8-K - Stock Titan
New Seres boss backs microbiome drug to keep cancer patients on treatment - Stock Titan
IPO Launch: Can STEL ride the EV waveQuarterly Trade Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving AverageWhat's Next? - MarketBeat
0.99%
3.03%
자본화:
|
볼륨(24시간):